Double blind, randomised, placebo controlled study to evaluate the safety, tolerability and pharmacokinetics of single doses of GSK1014802 and the effect of single doses of GSK1014802 or lamotrigine on resting motor threshold in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Vixotrigine (Primary) ; Lamotrigine
- Indications Absence epilepsy; Bipolar disorders; Depressive disorders; Lennox-Gastaut syndrome; Neuropathic pain; Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 18 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jul 2007 New trial record.